TAXOTERE

Country: Ísrael

Tungumál: enska

Heimild: Ministry of Health

Virkt innihaldsefni:

DOCETAXEL AS TRIHYDRATE 20 MG / 1 ML

Fáanlegur frá:

SANOFI - AVENTIS ISRAEL LTD

ATC númer:

L01CD02

Lyfjaform:

CONCENTRATE FOR SOLUTION FOR INFUSION

Stjórnsýsluleið:

I.V

Framleitt af:

SANOFI - AVENTIS DEUTSCHLAND GMBH, GERMANY

Meðferðarhópur:

DOCETAXEL

Ábendingar:

Breast cancer: Taxotere (docetaxel) in combination with doxorubicin and cyclophosphamide is indicated for the adjuvant treatment of patients with operable node- positive breast cancer. Taxotere (docetaxel) in combination with doxorubicin is indicated for the treatment of patients with locally advanced or metastatic breast cancer who have not previously received cytotoxic therapy for this condition. Taxotere(docetaxel) monotherapy is indicated for the treatment of patients with metastatic breast cancer after failure of cytotoxic therapy. Previous chemotherapy should have included an anthracycline or an alkylating agent. Taxotere (docetaxel) in combination with trastuzumab is indicated for the treatment of patients with metastatic breast cancer whose tumors overexpress HER2 and who previously have not received chemotherapy for metastatic disease. Taxotere (docetaxel) in combination with capecitabine is indicated for the treatment of patients with metastatic breast cancer after failure of cytotoxic chemotherapy.

Leyfisdagur:

2012-11-01